Research Update: CyberKnife for Prostate Cancer

If you’re considering CyberKnife® treatment for a prostate cancer diagnosis, below are two recently published studies to help you learn more about how CyberKnife can help you. The results of both studies support the safety and effectiveness of stereotactic body radiation therapy for prostate cancer, an advanced treatment approach that targets radiation to match the size and shape of a patient’s prostate cancer, minimizing damage to surrounding healthy tissue.

• Georgetown University published the results of their study titled, “Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer“Êin the Radiation Oncology Journal. The team reported that SBRT for clinically localized prostate cancer was well tolerated.

• A team of researchers in New York released the results of a study of more than 300 prostate cancer patients treated with CyberKnifeÊtechnology. The study titled, “Stereotactic Body Radiotherapy for Localized Prostate Cancer: Disease Control and Quality of Life at 6 Years,” detailed that no patients experienced advanced complications from treatment and the treatment option has distinct advantages over other treatment options such as high dose rate brachytherapy. Led by Dr. Alan Katz, the study is one of the largest of its kind.

These clinical studies are among the research that has prompted insurance providers and cancer organizations across the country to announce support and coverage of SBRT as an appropriate treatment option for prostate cancer. If you’re interested in learning more about how our center treats prostate cancer with SBRT, click here.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.